Conversely, a significant reduction in EpCAM expression was noted in colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), as well as in liver hepatocellular carcinoma (LIHC) and renal cancer (Fig. 2A). Here, EPCAM is linked to renal carcinoma.